Cardiff Oncology, Inc.
Datakwaliteit: 100%
CRDF
Nasdaq
Manufacturing
Chemicals
€ 1,58
▼
€ 0,09
(-5,39%)
Marktkapitalisatie: 114,85 M
Prijs
€ 1,68
Marktkapitalisatie
114,85 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Revenue grew 13,37% annually over 5 years — strong growth
Negative free cash flow of -37,97 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 26,55%
Capital efficient — spends only 7,42% of revenue on capex
Groei
Revenue Growth (5Y)
13,37%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)-13,18%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-85,39%
Onder sectorgemiddelde (-53,47%)
ROIC-71,53%
Net Margin-7732,04%
Op. Margin-8256,32%
Veiligheid
Debt / Equity
N/A
Current Ratio4,20
Interest CoverageN/A
Waardering
PE (TTM)
-2,50
Onder sectorgemiddelde (-1,48)
P/B Ratio2,35
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,5 | -1,5 |
| P/B | 2,4 | 1,6 |
| ROE % | -85,4 | -53,5 |
| Net Margin % | -7732,0 | -41,5 |
| Rev Growth 5Y % | 13,4 | 1,8 |
| D/E | — | 0,3 |
Koersdoel Analisten
8 analisten
Buy
Huidig
€ 1,58
Koersdoel
€ 7,75
€ 2,00
€ 9,25
€ 12,00
Vooruitzicht
Forward K/W
-2,26
Forward WPA
-€ 0,70
Omzet Sch.
246.430,0
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
-€ 0,70
-€ 0,83 – -€ 0,59
|
246.430,0 | 4 |
| FY2026 |
-€ 0,52
-€ 0,67 – -€ 0,37
|
338.890,0 | 5 |
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| 2026 Q2 |
-€ 0,12
-€ 0,16 – -€ 0,07
|
78.750,0 | 5 |
| 2026 Q1 |
-€ 0,12
-€ 0,16 – -€ 0,11
|
77.500,0 | 5 |
Winstverassingen
Laatste 4 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q42025 | -€ 0,20 | -€ 0,11 | +44,1% |
| Q32025 | -€ 0,21 | -€ 0,17 | +18,4% |
| Q22025 | -€ 0,20 | -€ 0,21 | -6,8% |
| Q12025 | -€ 0,19 | -€ 0,20 | -7,5% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -13,18% | Revenue Growth (3Y) | 10,23% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 13,37% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 593.000,0 | Net Income (TTM) | -45,85 M |
| ROE | -85,39% | ROA | -65,73% |
| Gross Margin | N/A | Operating Margin | -8256,32% |
| Net Margin | -7732,04% | Free Cash Flow (TTM) | -37,97 M |
| ROIC | -71,53% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4,20 |
| Interest Coverage | N/A | Asset Turnover | 0,01 |
| Working Capital | 47,10 M | Tangible Book Value | 48,79 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2,50 | Forward P/E | N/A |
| P/B Ratio | 2,35 | P/S Ratio | 193,68 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -33,06% | ||
| Market Cap | 114,85 M | Enterprise Value | 104,72 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,69 | Revenue / Share | 0,01 |
| FCF / Share | -0,56 | OCF / Share | -0,55 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 7,42% | FCF Conversion | 82,81% |
| SBC-Adj. FCF | -43,65 M | Growth Momentum | -26,55 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 593.000,0 | 683.000,0 | 488.000,0 | 386.000,0 | 359.000,0 |
| Net Income | -45,85 M | -45,43 M | -41,44 M | -38,70 M | -28,29 M |
| EPS (Diluted) | -0,69 | -0,95 | -0,93 | -0,89 | -0,73 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -48,96 M | -48,65 M | -45,41 M | -39,90 M | -28,86 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | 27,10 M | 17,40 M |
| SG&A Expenses | 14,22 M | 12,48 M | 13,04 M | 13,18 M | 11,84 M |
| D&A | 364.000,0 | 404.000,0 | 398.000,0 | 236.000,0 | 451.000,0 |
| Interest Expense | — | — | — | — | 0,0 |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 61,88 M | 97,19 M | 81,64 M | 116,19 M | 149,54 M |
| Total Liabilities | 16,50 M | 14,24 M | 11,90 M | 9,85 M | 9,13 M |
| Shareholders' Equity | 45,39 M | 82,95 M | 69,74 M | 106,34 M | 140,42 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 17,47 M | 51,47 M | 21,66 M | 16,35 M | 11,94 M |
| Current Assets | 60,13 M | 95,05 M | 77,41 M | 111,28 M | 146,13 M |
| Current Liabilities | 16,39 M | 13,43 M | 10,44 M | 7,81 M | 6,56 M |
{"event":"ticker_viewed","properties":{"ticker":"CRDF","listing_kind":"stock","pathname":"/stocks/crdf","exchange":"Nasdaq","country":"US"}}
